Alex Dorosheva is a technical advisor/law clerk who primarily supports the preparation and prosecution of biotechnology and life science patents, both U.S. and foreign. Alex received her B.S. in Biochemistry from Rider University, and Ph.D. in Pharmaceutical Sciences from University of North Carolina at Chapel Hill. Alex is currently pursuing a J.D. from Temple University Beasley School of Law, Evening Division (expected graduation 2024).
Prior to working in intellectual property law, Alex worked as a scientific researcher. She has extensive laboratory experience in the fields of biochemistry and protein engineering, cell and molecular biology, biopharmaceuticals, cell and gene therapy, and oncology. Alex’s dissertation work focused on developing a novel protein-decoy inhibitor for targeting an oncogenic pathway in uveal melanoma and utilizing gene therapy-based approaches (DNA/mRNA nano delivery systems (e.g., lipid nanoparticles) and viral vector systems (e.g., AAV)) for intracellular delivery for potential treatment development.
Publications co-authored by Alex include “Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis.” Adv. Mater., 480(52); “Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.” Nat. Commun., 9(1); “Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer.” ACS Nano, 11(9), 8690–8706; “Liver-specific gene immunotherapies resolve immune-suppressive ectopic lymphoid structures of liver metastases and prolong survival.” Biomaterials, 141(1), 260–271; “Structural elements that govern Sec14-like phosphatidylinositol transfer protein sensitivities to potent small molecule inhibitors.” J. Lipid Res., 57(4), 650-662.